Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Benchmark Co. 

Exact Sciences diskutieren

Exact Sciences

WKN: 590273 / Symbol: EXAS / Name: EXACT Sci / Aktie / Biotechnologie & medizinische Forschung / Large Cap /

86,55 €
-0,15 %

Einschätzung Buy
Rendite (%) 39,94 %
Kursziel 65,17
Veränderung
Endet am 04.11.26

Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Guggenheim from $70.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat

Einschätzung Buy
Rendite (%) 40,50 %
Kursziel 65,17
Veränderung
Endet am 04.11.26

Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Benchmark Co. from $60.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat

Exact Sciences (NASDAQ:EXAS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Ratings data for EXAS provided by MarketBeat

Einschätzung Buy
Rendite (%) 44,25 %
Kursziel 76,46
Veränderung
Endet am 04.11.26

Exact Sciences (NASDAQ:EXAS) was given a new $88.00 price target on by analysts at Robert W. Baird. They now have an "outperform" rating on the stock.
Ratings data for EXAS provided by MarketBeat

Einschätzung Buy
Rendite (%) 43,06 %
Kursziel 78,20
Veränderung
Endet am 04.11.26

Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at TD Cowen from $74.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat

Einschätzung Buy
Rendite (%) 42,80 %
Kursziel 73,96
Veränderung
Endet am 05.11.26

Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $85.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat

Einschätzung Buy
Rendite (%) 48,30 %
Kursziel 69,24
Veränderung
Endet am 11.11.26

Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Piper Sandler from $70.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat